Han Hee Yong, Park Sang Min, Lee Ji Hyun, Kim Chul Gu, Kim Jong Woo, Cho Han Joo, Kim Jae Hui
Department of Ophthalmology, Kim's Eye Hospital, #156 Youngdeungpo-dong 4ga, Youngdeungpo-gu, 150-034, Seoul, South Korea.
Sci Rep. 2025 Jan 6;15(1):938. doi: 10.1038/s41598-024-82746-4.
To evaluate the outcomes and predictive factors for fluid resolution following three loading injections of faricimab for neovascular age-related macular degeneration(AMD). This retrospective study included patients diagnosed with treatment-naïve neovascular AMD who received three monthly injections of faricimab. Changes in best-corrected visual acuity(BCVA) and central retinal thickness(CRT) following treatment were evaluated. The resolution of subretinal fluid(SRF), intraretinal fluid(IRF), and serous pigment epithelial detachment(PED) was also assessed. In addition, factors associated with complete resolution of SRF and IRF were investigated. A total of 69 patients were included in this study. BCVA significantly improved from a mean logarithm of minimal angle of resolution of 0.64 ± 0.41 at baseline to 0.47 ± 0.39 at 3 months (P < 0.001). CRT significantly decreased from 424.1 ± 155.5 μm at baseline to 266.3 ± 71.7 μm at 3 months (P < 0.001). At baseline, SRF was observed in 55 eyes (79.7%), IRF in 39 eyes(56.5%), and serous PED in 57 eyes(82.6%). By 3 months, the number of eyes showing these findings had decreased to 11 eyes(15.9%) for SRF, 6 eyes(8.7%) for IRF, and 10 eyes(14.5%) for serous PED. The presence of type 2 (88.2%) and type 3 (94.7%) macular neovascularization(MNV) was associated with a high incidence of complete resolution of SRF and IRF after treatment. Three loading injections of faricimab resulted in significant functional and anatomical improvements in treatment-naïve neovascular AMD, with a high rate of resolution of SRF, IRF, and serous PED. The anatomical effects were especially pronounced in cases of type 2 and type 3 MNV.
评估三次负荷注射法西单抗治疗新生血管性年龄相关性黄斑变性（AMD）后液体消退的结局及预测因素。这项回顾性研究纳入了被诊断为初治新生血管性AMD且接受了三个月度法西单抗注射的患者。评估了治疗后最佳矫正视力（BCVA）和中心视网膜厚度（CRT）的变化。还评估了视网膜下液（SRF）、视网膜内液（IRF）和浆液性色素上皮脱离（PED）的消退情况。此外，研究了与SRF和IRF完全消退相关的因素。本研究共纳入69例患者。BCVA从基线时平均最小分辨角对数0.64±0.41显著改善至3个月时的0.47±0.39（P<0.001）。CRT从基线时的424.1±155.5μm显著降至3个月时的266.3±71.7μm（P<0.001）。基线时，55只眼（79.7%）观察到SRF，39只眼（56.5%）观察到IRF，57只眼（82.6%）观察到浆液性PED。到3个月时，出现这些表现的眼数分别降至SRF的11只眼（15.9%）、IRF的6只眼（8.7%）和浆液性PED的10只眼（14.5%）。2型（88.2%）和3型（94.7%）黄斑新生血管（MNV）的存在与治疗后SRF和IRF完全消退的高发生率相关。三次负荷注射法西单抗使初治新生血管性AMD在功能和解剖学上有显著改善，SRF、IRF和浆液性PED的消退率很高。在2型和3型MNV病例中，解剖学效果尤为明显。
